Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > OctoPlus wins expansion of drug delivery evaluation contract with existing client

Abstract:
OctoPlus N.V. ("OctoPlus") (Euronext: OCTO), the drug delivery company, announces today that it has won an expansion of a drug delivery technology evaluation contract with an existing client, a global pharmaceutical company. In 2008 and 2009 OctoPlus performed preliminary feasibility work for this client and with the results from these studies the client has decided to proceed with the evaluation of OctoPlus' technology for a product candidate in its pipeline.

OctoPlus wins expansion of drug delivery evaluation contract with existing client

Leiden, the Netherlands | Posted on September 8th, 2009

In October last year OctoPlus announced a strategic focus on developing controlled release versions of existing or new drugs for clients, in addition to providing general formulation development and clinical material manufacturing. This is the fourth compound in 2009 for which OctoPlus will work on a controlled release formulation.

Under the contract announced today, OctoPlus will evaluate the feasibility of a controlled release formulation that combines the client's product candidate with OctoPlus' proprietary drug delivery technology. If the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement.

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

####

About OctoPlus
OctoPlus is a product-oriented biopharmaceutical company committed to the creation of improved pharmaceutical products that are based on OctoPlus’ proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.

The clinically most advanced product incorporating our technology is Biolex Therapeutics’ lead product Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. Locteron is being manufactured for Biolex Therapeutics by OctoPlus and is currently in Phase IIb clinical studies.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO.

For more information, please click here

Contacts:
Rianne Roukema
Corporate Communications
+31 (71) 524 1071
or send an e-mail to Investor Relations at

Copyright © OctoPlus

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Crystal light: New light-converting materials point to cheaper, more efficient solar power: University of Toronto engineers study first single crystal perovskites for new solar cell and LED applications January 30th, 2015

Hiden Gas Analysers at PITTCON 2015 | Visit us on Booth No. 1127 January 29th, 2015

Discovery Channel taps Angstron Materials for segment featuring graphene advances January 29th, 2015

Asteroid Mining 101: A New Book by World-Renowned Expert Dr. John S. Lewis - Exclusive Sneak-Peek Opportunity for Book Reviewers and Media January 29th, 2015

Nanomedicine

Made-in-Singapore rapid test kit detects dengue antibodies from saliva: IBN's MedTech innovation simplifies diagnosis of infectious diseases January 29th, 2015

Iranian Researchers Planning to Produce Edible Insulin January 28th, 2015

Nanoparticles that deliver oligonucleotide drugs into cells described in Nucleic Acid Therapeutics January 28th, 2015

Nanoliposomes Help Efforts to Cure Bacterial Infections January 27th, 2015

Announcements

Crystal light: New light-converting materials point to cheaper, more efficient solar power: University of Toronto engineers study first single crystal perovskites for new solar cell and LED applications January 30th, 2015

Park Systems Announces Innovations in Bio Cell Analysis with the Launch of Park NX-Bio, the only 3-in-1 Imaging Nanoscale Tool Available for Life Science Researchers January 29th, 2015

2015 Nanonics Image Contest January 29th, 2015

Iranian Scientists Use MOFs to Eliminate Dye Pollutants January 29th, 2015

Nanobiotechnology

Spider electro-combs its sticky nano-filaments January 28th, 2015

Nanoshuttle wear and tear: It's the mileage, not the age January 26th, 2015

Engineering self-assembling amyloid fibers January 26th, 2015

DNA 'glue' could someday be used to build tissues, organs January 14th, 2015

Alliances/Partnerships/Distributorships

The Original Frameless Shower Doors Installs DFI's FuseCube™ to Offer Hydrophobic Protective Coating as a Standard Feature: First DFI FuseCube™ Installed on the East Coast to Enable Key Differentiator for the Original Frameless Shower Doors January 29th, 2015

Entanglement on a chip: Breakthrough promises secure communications and faster computers January 27th, 2015

Smart keyboard cleans and powers itself -- and can tell who you are January 21st, 2015

DNA 'glue' could someday be used to build tissues, organs January 14th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE